Côte d’Ivoire has become the first country to begin administering the new R21/Matrix-M vaccine.
The delivery of the first shot marks a significant milestone in the global fight against malaria, a disease which claims 600,000 lives annually in Africa.
The jab was developed through a collaboration between the University of Oxford and Serum Institute of India, utilizing Novavax's (Nasdaq: NVAX) Matrix-M adjuvant technology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze